Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are building the right side of a
consolidation after breaking above short-term resistance (S&P 500: 3,430, Nasdaq: 11,400). The distribution
day count remains elevated at seven and five, respectively, but two days will expire on the S&P 500 and one on
the Nasdaq next week.

Dr. Lal PathLabs

Key points from this report:

 

  • Buy Dr. Lal PathLabs: The stock broke out of a 10-week flat base on 9x average daily volume.
  • Positive read-through: Dr. Lal PathLabs’ competitors Metropolis Healthcare (MEP.IN) and Thyrocare Technologies (ZTY.IN) announced positive business updates for the quarter ending September. Their ex-COVID businesses have normalized in September versus last year, as easing lockdown restrictions aided in a better-than-expected business recovery.
  • Better positioning among peers: The company is the largest branded diagnostic chain in India in terms of samples processed. In FY20, the company processed 47.7M (+14% y/y) samples from 19.4M (+10% y/y) patients, compared with its nearest competitor, SRL Diagnostic (owned by Fortis Healthcare (FTH.IN)), at 30M samples. Over the last four quarters, the number of samples processed by the company has increased 14.5% on average.

Market View

U.S. Market
The U.S. market has shifted back to a Confirmed Uptrend. The status change was made after Thursday’s close
as both indices regained their respective 50-DMA, a multitude of quality growth ideas turned actionable, and
distribution was avoided for seven straight sessions ahead of a period where multiple days will begin to expire.
On Friday, indices pulled back to their respective 50-DMA, though little damage was done to leading stocks
given sizable gains earlier in the week. The S&P 500 added an eighth distribution day, though four will expire
over the next eight sessions. The Nasdaq’s count went unchanged at five total, with two set to expire over that
same time frame.

PerkinElmer

Key points from this report:

 

  • Buy PerkinElmer (PKI). The stock is actionable after breaking out from a seven-week flat base in heavy volume. Add to positions.
  • PerkinElmer has a top three market position in 65–70% of its product lines. Driven by increasing diagnostic revenue, recurring revenue now accounts for 75% of total revenue, up from 55% in 2014.
  • The company is now the global leader in biochemical prenatal testing, newborn screening, and global autoimmune in vitro diagnostics. Through this improving product mix as well as geographic expansion, the company has tripled its TAM to ~$50B.

Market View

U.S. Market
The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq closed the week on a strong
note, rallying sharply off price support and now set to face resistance at their respective 50-DMA (S&P 500:

3,351; Nasdaq: 11,025). Distribution remains elevated at seven and six days, respectively, with one day expir-
ing on the Nasdaq next Wednesday.

Market View

The U.S. market remains in an Uptrend Under Pressure. The S&P 500 and Nasdaq are both now trading slightly
below their respective 50-DMA with six distribution days each. One distribution day will expire on the Nasdaq
next Wednesday. The S&P 500 is trading ~7% off highs with the next level of support at ~3,233, while the
Nasdaq is trading ~11% off highs with near-term support at ~10,700 before ~10,200. Both indices are being
dragged lower by big-cap tech as the majority of other leading ideas continue to base constructively.